Investor Relations Home
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus - both of which are undergoing Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor, expected to enter into a Phase 2 clinical trial for the treatment chronic dry eye.
|06/04/13||Rigel Will Resume Responsibility for Fostamatinib Program|
|Fostamatinib at 100mg BID Significantly Improves Rheumatoid Arthritis in Both OSKIRA-2 & OSKIRA-3
SOUTH SAN FRANCISCO, Calif., June 4, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA).
In the OSKIRA-2 study of ... |
|05/22/13||Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye|
|Two Partnered Oncology Programs to Initiate Clinical Trials
SOUTH SAN FRANCISCO, Calif., May 22, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being developed by Rigel as a treatment for dry eye disease. The other two programs are aimed at oncology targets and are being conducted by corporate partners, ... |
|There are currently no events scheduled.|
|* Data collected 06/12/13 - 06/19/13|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.